title: Generation of an autologous cell system for immunotherapy of squamous cell carcinoma of the head and neck.
abstract: BACKGROUND
  To date, there is no tumor antigen known to be sufficiently specific for diagnosis, therapy monitoring and immunotherapy of squamous cell carcinoma of the head and neck (SCCHN). The aim of our study was to generate an autologous immune response against SCCHN in vitro for further characterization of SCCHN-specific tumor markers and adoptive immunotherapy.
  
  
  METHODS
  As sources for tumor antigens (Ags) for the restimulation of autologous immune cells, cell lines from solid SCCHN were established and characterized. Forty-five percent of 40 tumors of different SCCHN specimens were maintained for more than 20 cell generations in culture.
  
  
  RESULTS
  One primary cell line, SCCHN-GHD, newly established from a hypopharynx carcinoma, was further characterized as a telomerase-positive, immortalized cell line with epithelial cell characteristics. It was found to be tumorigenic in SCID mice.
  
  
  CONCLUSIONS
  This new SCCHN-GHD cell line is competent as a target for lysis by autologous immune cells and for the restimulation of autologous tumor-specific immune cells. Subsequent characterization of tumor antigens will be performed.
authors.affiliation: GSF-National Research Center for Environment and Health, Department of Comparative Medicine, Neuherberg, Germany.
authors.forename: Anna
authors.initials: A
authors.lastname: Mayer
authors.forename: Michaela
authors.initials: M
authors.lastname: Andratschke
authors.forename: Christof
authors.initials: C
authors.lastname: Pauli
authors.forename: Hendrik
authors.initials: H
authors.lastname: Graefe
authors.forename: Kolbow
authors.initials: K
authors.lastname: Kristina
authors.forename: Barbara
authors.initials: B
authors.lastname: Wollenberg
mesh_terms: D000818:Animals; D002294:Carcinoma, Squamous Cell / Q000276:immunology* / Q000628:therapy*; D016207:Cytokines / Q000096:biosynthesis / Q000276:immunology; D006258:Head and Neck Neoplasms / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007376:Interleukin-2 / Q000494:pharmacology; D007963:Leukocytes, Mononuclear / Q000276:immunology; D051379:Mice; D016513:Mice, SCID; D011994:Recombinant Proteins / Q000494:pharmacology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
chemical_list: D016207:Cytokines; D007376:Interleukin-2; D011994:Recombinant Proteins